MedTrace Logo

Smoldering Inflammation in MS

NCT06591429 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2026-04-28

No results posted yet for this study

Summary

The goal of this observational study is to learn about inflammation in those with relapsing remitting Multiple Sclerosis (MS). The main questions it aims to answer are:

* How does abnormal neural inflammation compare to cellular and molecular inflammation in MS?
* Once treated, why does abnormal inflammation persist?

Conditions

Interventions

RADIATION

Radiotracer [11C]-CS1P1

Radiotracer used in PET/CT scans of the head and neck Dose range: 12-17 mCi

RADIATION

Radiotracer [11C]-DPA-713

Radiotracer used in PET/CT scans of the head and neck Dose range:15-20 mCi

DRUG

anti-CD20 MS treatment

MS treatment taken indepenently after initial testing

RADIATION

Radiotracer [12F]-FDG

used in PET/CT scans of the head and neck Dose: 5-7 mCi

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-19
Primary Completion
2027-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06591429 on ClinicalTrials.gov